Skip to main content
Explore URMC

menu

Leukemia (AML): Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Research Question:
There is no research question. This is an expanded access program.

Basic Study Information

Purpose:
This is an expanded access program. The program is sponsored by the pharmaceutical company named Agios Pharmaceuticals, Inc. (the "Sponsor"). The purpose of this EAP is to provide access to ivosidenib to qualifying patients during the period of time prior to the potential approval and commercial availability of ivosidenib.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03245424?term=AG120-C-010&rank=1
Study Reference #: ELEU18003

Lead Researcher (Principal Investigator)

Lead Researcher: Jason Mendler

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Leukemia, Myeloid, Acute

Return to Search